(2R,3S)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoic acid | 62023-60-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2R,3S)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoic acid
• 英文别名: (2R,3S)-N-(benzyloxycarbonyl)-3-amino-2-hydroxy-4-phenylbutanoic acid；Z-(2R,3S)-AHPA；3-Benzyloxycarbonylamino-2-hydroxy-4-phenyl-butyric acid；(2R,3S)-2-hydroxy-4-phenyl-3-(phenylmethoxycarbonylamino)butanoic acid
• CAS: 62023-60-3
• 化学式: C₁₈H₁₉NO₅
• 分子量: 329.353
• InChiKey: JXJYTERRLRAUSF-JKSUJKDBSA-N

物化性质

• 沸点：
  581.9±50.0 °C(Predicted)
• 密度：
  1.295±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  95.9
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2R,3S)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoic acid 在 钯 氢气 作用下， 生成 (2R,3S)-3-氨基-2-羟基-4-苯丁酸
  参考文献：
  名称：

  Synthesis and structure-activity relations of bestatin analogs, inhibitors of aminopeptidase B

  摘要：

  Stereoisomers and analogues of bestatin, [(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-L-leucine, were synthesized and tested for aminopeptidase B and leucine aminopeptidase inhibiting activity. Among the eight stereoisomers, the 2S stereoisomers exhibited strong activity. In a series of compounds in which the L-leucine residue of bestatin was substituted with other amino acids, only the one containing isoleucine showed more activity than bestatin. Norleucine, norvaline, methionine, valine, serine, glutamine, phenylalanine, glutamic acid, proline, and lysine analogues gave, in that order, decreasing activity. Alkyl and phenyl sub stitution for the benzyl group of bestatin decreased the activity markedly. p-Methyl-, p-chloro-, and p-nitrobestatins showed greater activity than bestatin.

  DOI：

  10.1021/jm00214a010
• 作为产物：
  描述：

  苄基(S)-1-(N-甲氧基-N-甲基氨基甲酰基)-2-苯乙基氨基甲酸酯 在 lithium hydroxide 、 sodium tetrahydroborate 、 叔丁基锂 、 臭氧 、 magnesium bromide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 0.83h， 生成 (2R,3S)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoic acid
  参考文献：
  名称：

  Selectivity in the Inhibition of HIV and FIV Protease: Inhibitory and Mechanistic Studies of Pyrrolidine-Containing .alpha.-Keto Amide and Hydroxyethylamine Core Structures

  摘要：

  This paper describes the development of new pyrrolidine-containing alpha-keto amide and hydroxyethylamine core structures as mechanism based inhibitors of the HIV and FIV proteases. It was found that the alpha-keto amide core structure 2 is approximately 300-fold better than the corresponding hydroxyethylamine isosteric structure and 1300-fold better than the corresponding phosphinic acid derivative as an inhibitor of the HIV protease. The alpha-keto amide is however not hydrated until it is bound to the HIV protease as indicated by the NMR study and the X-ray structural analysis. Further analysis of the inhibition activities of hydroxyethylamine isosteres containing modified pyrrolidine derivatives revealed that a cis-methoxy group at C-4 of the pyrrolidine would improve the binding 5-and 25-fold for the trans-isomer. When this strategy was applied to the alpha-keto amide isostere, a cis-benzyl ether at C-4 was found to enhance binding 3-fold. Of the core structures prepared as inhibitors of the HIV protease, none show significant inhibitory activity against the mechanistically identical FIV protease, and additional complementary groups are needed to improve inhibition.

  DOI：

  10.1021/ja00153a008

文献信息

• Use of glycogen phosphorylase inhibitors
  申请人：——

  公开号：US20030004162A1

  公开（公告）日：2003-01-02

  The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

  本发明提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用有效量的糖原磷酸化酶抑制剂；有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。本发明还提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用包含有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂的药物组合物；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。
• HIV protease inhibitors
  申请人：Wong Chi-Huey

  公开号：US06900238B1

  公开（公告）日：2005-05-31

  Combinatorial libraries of HIV and FIV protease inhibitors are characterized by α-keto amide or hydroxyethylamine core structures flanked by on one side by substituted pyrrolidines, piperidines, or azasugars and on the other side by phenylalanine, tyrosine, or substituted tyrosines. The libraries are synthesized via a one step coupling reaction. Highly efficacious drug candidates are identified by screening the libraries for binding and inhibitory activity against both HIV and FIV protease. Drug candidates displaying clinically useful activity against both HIV and FIV protease are identified as being potentially resistive against a loss of inhibitory activity due to development of resistant strains of HIV.

  HIV和FIV蛋白酶抑制剂的组合库以α-酮酰胺或羟乙基胺核心结构为特征，一侧为取代吡咯烷、哌啶或氮代糖，另一侧为苯丙氨酸、酪氨酸或取代酪氨酸。这些库是通过一步偶联反应合成的。通过筛选这些库，识别出对HIV和FIV蛋白酶的结合和抑制活性高效的药物候选化合物。对HIV和FIV蛋白酶都显示出临床有用活性的药物候选化合物被确定为潜在对抗由于HIV耐药株的发展而导致的抑制活性丧失。
• Synthesis of a cis-conformationally restricted peptide bond isostere and its application to the inhibition of the HIV-1 protease
  作者：Andrew D. Abell、Glenn J. Foulds

  DOI：10.1039/a702458d

  日期：——

  A synthesis of a new, tetrazole-based, cis-constrained hydroxyethylamine peptide bond isostere is reported. This has been used to produce a new class of HIV-1 protease inhibitor.

  报告了一种新的、基于四氮唑的顺式受约束羟乙基胺肽键异构体的合成。该化合物已被用于生产一种新型的 HIV-1 蛋白酶抑制剂。
• Tributyltin Cyanide, a Novel Reagent for the Stereoselective Preparation of 3-Amino-2-hydroxy Acids via Cyanohydrin Intermediates
  作者：Rosario Herranz、Julia Castro-Pichel、Teresa García-López

  DOI：10.1055/s-1989-27367

  日期：——

  Reaction of tributyltin cyanide with optically active 2-N-benzyloxyearbonylamino aldehydes 1 gives the corresponding O-tributylstannyl cyanohydrins 2 and 3 stereoselectively. Compounds 2 and 3 are transformed in situ into the methyl 3-N-benzoyloxycarbonyl-amino-2-hydroxy esters 4 and 5, respectively, via the imidate hydrochloride intermediates. Saponification of 4 and 5 provide 3-amino-2-hydroxy acids 6 and 7, respectively, key intermediates in the preparation of Bestatin, Amastatin, and analogues.

  三丁基氰化锡与光学活性2-N-苯甲氧羰基氨基醛1反应立体选择性地得到相应的O-三丁基甲锡烷基氰醇2和3。化合物2和3通过亚氨酸盐酸盐中间体分别原位转化为甲基3-N-苯甲酰氧基羰基-氨基-2-羟基酯4和5。 4和5的皂化分别提供3-氨基-2-羟基酸6和7，它们是制备Bestatin、Amastatin和类似物的关键中间体。
• Stereoselection in the synthesis of threo- and erythro-3-amino-2-hydroxy-4-phenyl-butanoic acid using chiral acetal templates
  作者：Rosario Herranz、Julia Castro-Pichel、Soledad Vinuesa、M. Teresa García-López

  DOI：10.1039/c39890000938

  日期：——

  derived from Z-L- and Z-D-phenyl alaninal, (Z=N-benzyloxycarbonyl), and (+)-(2S,4S)- and (–)-(2R,4R)-2,4-pentanediol stereoselectively gave the four stereoisomers of the 3-amino-2-hydroxy-4-phenylbutanoic acid, key intermediates for bestatin and bestatin analogues.

  三氟化硼-乙醚介导的三甲基甲硅烷基氰化物（TMSCN ）加到衍生自Z- L-和Z- D-苯基丙氨酸，（Z = N-苄氧羰基）和（+）-（2 S，4 S）的手性缩醛中-和（-）-（2 R，4 R）-2,4-戊二醇立体选择得到3-氨基-2-羟基-4-苯基丁酸的四种立体异构体，这是Bestatin和Bestatin类似物的关键中间体。